| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(4 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(6 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(7 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(5 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(6 years from now) | |
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(12 years from now) | |
Kisqali is owned by Novartis.
Kisqali contains Ribociclib Succinate.
Kisqali has a total of 8 drug patents out of which 0 drug patents have expired.
Kisqali was authorised for market use on 13 March, 2017.
Kisqali is available in tablet;oral dosage forms.
Kisqali can be used as in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer.
The generics of Kisqali are possible to be released after 14 April, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 10, 2024 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
Market Authorisation Date: 13 March, 2017
Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-ba...
Dosage: TABLET;ORAL
KISQALI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic